<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114902</url>
  </required_header>
  <id_info>
    <org_study_id>CT-44 Study Protocol AFTM-01</org_study_id>
    <nct_id>NCT05114902</nct_id>
  </id_info>
  <brief_title>PCV13 Impact on Pneumococcal Nasopharyngeal Carriage Study</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Assessing the Impact of PCV13 on Pneumococcal Nasopharyngeal Colonization in Children 8 Weeks to ≤60 Months of Age Hospitalized for Pneumonia in the Philippines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Foundation for Tropical Medicine Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philippine Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Philippines Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asian Foundation for Tropical Medicine Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational, hospital based, nasopharyngeal carriage (NPC), vaccine&#xD;
      effectiveness study Comparisons will be made in Filipino children, aged 8 weeks to ≤60 months&#xD;
      of age at enrollment, who have been hospitalized with a radiologically-confirmed,&#xD;
      community-acquired pneumonia (CAP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be the first of two phases (A and B). Phase A will compare a PCV13-vaccinated&#xD;
      setting (SPMC) with an unvaccinated setting (PCMC)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>S. pneumoniae serotypes</measure>
    <time_frame>Upon Admission</time_frame>
    <description>S. pneumonia serotypes isolated from the nasopharynx of children admitted in PCV13-unvaccinated site (PCMC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>S. pneumoniae serotypes Upon Admission</measure>
    <time_frame>Upon Admission</time_frame>
    <description>S. pneumonia serotypes isolated from the nasopharynx of children admitted in PCV13-unvaccinated site (SPMC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antimicrobial resistance rate of S. pneumoniae</measure>
    <time_frame>Upon Admission</time_frame>
    <description>Antimicrobial resistance rate isolated from the nasopharynx of children admitted as a case of radiologic CAP admitted in PCV13- unvaccinated site (PCMC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antimicrobial resistance rate of S. pneumoniae</measure>
    <time_frame>Upon Admission</time_frame>
    <description>Antimicrobial resistance rate isolated from the nasopharynx of children admitted as a case of radiologic CAP admitted in PCV13-vaccinated site (SPMC)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>PCV13 Non-vaccinated Settting</arm_group_label>
    <description>Pneumococcal vaccine-naïve children at the PCMC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV13 Vaccinated Setting</arm_group_label>
    <description>Pneumococcal vaccine-exposed children at the SPMC</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasopharyngeal swab</intervention_name>
    <description>A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage</description>
    <arm_group_label>PCV13 Non-vaccinated Settting</arm_group_label>
    <arm_group_label>PCV13 Vaccinated Setting</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The retained specimen will consist of isolates of Streptococcus pneumoniae cultured from the&#xD;
      nasopharyngeal swab.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children 8 weeks to ≤60 months of age from the National Capital Region (NCR) or Region&#xD;
        X-XIII admitted with a medical diagnosis of clinical community-acquired pneumonia (CAP),&#xD;
        confirmed by an abnormal chest x-ray. In Region X-XIII, the child must have received at&#xD;
        least 1 dose of PCV13 given at &lt;12 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Child 8 weeks to ≤60 months of age&#xD;
&#xD;
          2. Resident of the National Capital Region (NCR) or Region X-XIII&#xD;
&#xD;
          3. Child admitted with a medical diagnosis of clinical CAP based on history and physical&#xD;
             exam&#xD;
&#xD;
          4. Written informed consent obtained from a parent or legal guardian&#xD;
&#xD;
          5. At SPMC site, child must have received at least 1 dose of PCV13 given at &lt;12 months&#xD;
             based on history-taking&#xD;
&#xD;
          6. For Phase B at PCMC site, child must have received at least 1 dose of PCV13 given at&#xD;
             &lt;12 months based on history-taking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Children with a known primary or secondary immunodeficiency&#xD;
&#xD;
          2. Child with a contraindication to doing a nasopharyngeal swab which may include, but is&#xD;
             not limited to: dyscrasias, coagulation disorders, or other diseases (e.g.,&#xD;
             hemophilia, purpura), presence of craniofacial abnormalities32&#xD;
&#xD;
          3. For Phase A at PCMC site, child with any PCV in the past based on history-taking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilla G Lucero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Foundation for Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marilla G Lucero, MD</last_name>
    <phone>+639178258541</phone>
    <email>marillaluceroscs@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaime Santos, MD</last_name>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Foundation for Tropical Medicine Inc.</investigator_affiliation>
    <investigator_full_name>Marilla Lucero</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Clinical CAP based on history and physical exam and radiological confirmation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

